MedTrace Logo

Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker

NCT03659643 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-09-06

No results posted yet for this study

Summary

Multi center study of six Memory Clinics in four Nordic countries in validating a prognostic diagnostic investigation of qEEG in Mild Cognitive Impairment (MCI). The study is in two parts, the first one is a follow up of a previous study conducted in 2011-2013 and the second half is new recruitment with two years follow up. End points are diagnosis of a dementing disorder, primarily dementia of Alzheimer´s type.

Conditions

Interventions

DIAGNOSTIC_TEST

EEG with SPR analysis

qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.

Sponsors & Collaborators

  • Ullevaal University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Zealand University Hospital

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • Kavli Research Foundation, Bergen Norway

    collaborator UNKNOWN

  • Jon Snaedal

    lead OTHER

Principal Investigators

  • Knut Engedal, PhD · Ullevaal University Hospital. Oslo, Norway

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-10-01
Completion
2020-10-01

Countries

  • Iceland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659643 on ClinicalTrials.gov